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Background: Delirium affects 15% of hospitalised patients and is linked with poor outcomes, yet few pharmacological
treatment options exist. One hypothesis is that delirium may in part result from exaggerated and/or prolonged stress
responses. Dexmedetomidine, a parenterally-administered alpha2-adrenergic receptor agonist which attenuates
sympathetic nervous system activity, shows promise as treatment in ICU delirium. Clonidine exhibits similar
pharmacodynamic properties and can be administered orally. We therefore wish to explore possible effects of
clonidine upon the duration and severity of delirium in general medical inpatients.
Methods/Design: The Oslo Study of Clonidine in Elderly Patients with Delirium (LUCID) is a randomised,
placebo-controlled, double-blinded, parallel group study with 4-month prospective follow-up. We will recruit
100 older medical inpatients with delirium or subsyndromal delirium in the acute geriatric ward. Participants will
be randomised to oral clonidine or placebo until delirium free for 2 days (Diagnostic and Statistical Manual of
Mental Disorders (DSM-5) criteria), or after a maximum of 7 days treatment. Assessment of haemodynamics (blood
pressure, heart rate and electrocardiogram) and delirium will be performed daily until discharge or a maximum of
7 days after end of treatment. The primary endpoint is the trajectory of delirium over time (measured by Memorial
Delirium Assessment Scale). Secondary endpoints include the duration of delirium, use of rescue medication for
delirium, pharmacokinetics and pharmacodynamics of clonidine, cognitive function after 4 months, length of hospital
stay and need for institutionalisation.
Discussion: LUCID will explore the efficacy and safety of clonidine for delirium in older medical inpatients.
Trial registration: ClinicalTrials.gov NCT01956604. EudraCT Number: 2013-000815-26
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alpha-2 Receptor AgonistsBackground
Delirium in hospitalised medical patients
Delirium commonly affects older people with acute
medical illness [1,2]. It is associated with patient dis-
tress, increased length of stay, higher risk of new insti-
tutionalisation, higher mortality, and an increased risk
of future dementia [3-6]. Despite its impact, delirium* Correspondence: bjorn.erik@neerland.net
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unless otherwise stated.remains poorly understood and few treatment options
are available.
The prevalence of delirium is at least 15% in hospita-
lised medical patients [7-9]. In patients with dementia
the prevalence is even higher, being up to 50 % in medical
wards [10]. Old age and pre-existing cognitive impairment
are the most important predisposing factors for delirium
[1,9], but, in principle, any acute medical condition can
precipitate delirium in a vulnerable individual [7]. Sub-
syndromal delirium is a clinical condition that falls on a
continuum between no symptoms and delirium defined
by the Diagnostic and Statistical Manual of Mentalal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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progress to full-scale delirium, and is a clinically important
condition associated with poor outcomes. Efforts to
prevent, detect and treat subsyndromal delirium are
thus justified.
Pathophysiology of delirium
The pathophysiology of delirium remains poorly under-
stood. Leading hypotheses focus on neurotransmission,
inflammation and acute stress as possible mechanisms
[12]. Decreased cholinergic activity and increased dopa-
minergic activity in the central nervous system (CNS)
are commonly postulated, with these neurotransmitter
deficits resulting from multiple precipitants. A causal
association between inflammation (pro-inflammatory
cytokines) and delirium has also been proposed [13,14].
Another hypothesis implies that delirium may be the
result of aberrant stress responses [13] as delirium com-
monly follows stress (physical or psychological). And
whilst stress responses are adaptive in young people,
they might be altered with ageing, leading to exaggerated
and more prolonged stress responses. This hypothesis
would also imply alterations of autonomic nervous
system activity in patients with delirium [15].
Pharmacological treatment of delirium
The hyperactive form of delirium is frequently treated
pharmacologically, but the effect of different treatment
modalities is poorly studied. The drug treatment of
hypoactive delirium has hardly been evaluated at all.
Thus more research on pharmacological treatment
options for delirium is urgently needed. Haloperidol
[16,17] and other antipsychotics (olanzapine [18], ris-
peridone [19] and quetiapine [20]) are commonly used,
and there is some, although weak, evidence of their effi-
cacy [21,22]. There is no evidence on the effects of anti-
psychotics in patients with delirium superimposed upon
dementia. For patients with parkinsonism or dementia
with Lewy bodies, antipsychotics are generally avoided,
leaving even fewer treatment options for these patients.
Antipsychotics have several drawbacks, including an
increased risk of death and cardiovascular events, sed-
ation, falls risk, and cognitive impairment [23]. These
risks increase with age, dementia and disability. This
calls for special caution for patients with delirium super-
imposed on dementia [21]. Benzodiazepines and other
sedatives are also frequently used, but the evidence sup-
porting these agents is even weaker [24]. There is no
clear evidence for the efficacy of cholinesterase inhibi-
tors in the treatment of delirium [25-27].
Alpha-2-adrenoreceptor agonists
Dexmedetomidine and clonidine are both alpha-2-
adrenoceptor agonists activating presynaptic inhibitoryalpha-2-adrenoreceptors. Clonidine is a partial agonist
with an alpha-2a-to-alpha-1 selectivity ratio of 39. For
dexmedetomidine this ratio is 1300 [28]. They exert a
general inhibitory influence on the sympathetic nervous
system, in particular due to CNS effects [29]. Dexmede-
tomidine decreases sympathetic activity and attenuates
the hemodynamic and neuroendocrinal stress responses
(including of cortisol), resulting in decreased heart rate
(HR) and blood pressure (BP) as well as sedative and
analgesic effects [30]. In the intensive care setting, both
substances reduce the need for opioids and sedatives
[31]. Dexmedetomidine is increasingly used in intensive
care patients, and is also used as an adjuvant during
regional anaesthesia. Recently conducted studies indi-
cate that the incidence of delirium is lower in intensive care
patients receiving dexmedetomidine than in those receiving
benzodiazepines [32,33], propofol [34] or morphine [35].
Currently available evidence thus suggests that dexmedeto-
midine may have value in the prevention and treatment
of delirium in the intensive care unit [36,37]. Indeed, it
is now in clinical use in the USA and Europe [38].
Most patients with delirium are however treated out-
side of intensive care units, where intravenous use of
dexmedetomidine is not feasible. An alternative agent
might thus be orally administred clonidine, which has very
similar pharmacodynamics to that of dexmedetomidine
[31], even though its alpha-2 selectivity is somewhat lower
[28]. Clonidine additionally has an independent stimula-
tory effect on the parasympathetic activity and a slight
anti-inflammatory effect [39,40], further making it an
interesting candidate for delirium treatment. This does
also accord with the hypothesis of delirium as a conse-
quence of aberrant stress responses [13].
Clinical experience with clonidine
Clonidine has been used as an anti-hypertensive drug for
decades, as well as for anesthesia-related applications,
such as perioperative analgesia [29,41], sedation and
anxiolysis, and for management of both acute postopera-
tive, chronic and neuropathic pain [41-43]. In one study,
use of intravenous clonidine after surgical correction of
acute type-A aortic dissection reduced the severity of de-
lirium, improved the respiratory function and shortened
the length of stay in the intensive care unit [44].
The adverse effects of clonidine include orthostatic
hypotension, bradycardia and AV-block. Such effects are,
however, dependent on dosage. In a previous report,
low-dose treatment (75 μg) in healthy adults was associ-
ated with a reduction in heart rate from 72 beats/min to
63 beats/min, and a reduction in mean arterial pressure
(MAP) from 88 mmHg to 75 mmHg. Less than 50%
experienced sedation, dry mouth or dizziness, and for
those who reported any of these side-effects, the severity
was mild [45]. Clonidine has been studied in outpatients
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Parkinson's disease [48,49]. Treatment with daily doses
of clonidine less than 200 mcg was well tolerated in
these patients. Relative contraindications to clonidine
for its licensed indications include bradyarrhythmias,
polyneuropathy, renal insufficiency and evidence of
reduced cerebral and/or peripheral circulation due to
vessel disease
Pharmacokinetics of clonidine
Maximum plasma concentration (Cmax) following oral
administration occurs after 1–3 h [45] and reduction in
mean arterial pressure as well as the risk of side effects
is highest at this peak. Cmax and area under the
concentration-time-curve (AUC) increase proportionally
with increasing doses. Clonidine traverses the blood–
brain-barrier. The half-life during the elimination phase
shows great inter-individual variation and is found to be
between 5 and 25.5 hours. The metabolism is hepatic
and the metabolites are inactive. Clonidine is mainly
excreted renally (70%).
Rationale for dosage plan of clonidine
A dosage plan for clonidine is presented in Table 1. Be-
cause we are studying short-term use in an acute setting,
we want to achieve steady-state (serum concentration
levels) more quickly by using loading doses (day 1)
under close monitoring of blood pressure. On days 2–7
we will administer a lower maintenance dose. We will
thus give 75 μg clonidine every 3rd hour up to a max-
imum of 4 doses on day 1, and then 75 μg twice per day.
Concentration levels of clonidine known to have
clinical effects range from 0.2 to 2.0 ng/ml [50-52]. We
are aiming for the lower levels, that is, between 0.3 ng/ml
(median trough concentration) and 0.7 ng/ml (maximal
concentration), because higher plasma concentration
levels increases the risk of adverse events, including
hypotension. Nonetheless, lower plasma concentration
levels may be insufficient to give a significant effect on
our primary endpoint.
To our knowledge, there are no studies of the rela-
tionship between plasma concentration of clonidine andTable 1 Dosage plan for clonidine
Time Safety
Day 1 Systolic BP has to be >120 mmHg before the fir
Loading doses If systolic BP is <100 mmHg, HR <50 beats/min,
before any of the subsequent loading doses, no
will be given until the planned maintenance do
If RASS is −2, the treating physician has to asses
Day 2-7 If systolic BP is <100 mmHg, HR <50 beats/min,
just before a planned dose, no study medication
next planned dose 12 hours later.Maintenance doses
If RASS is −2, the treating physician has to assesdelirium. In publications on the effect on delirium of dex-
medetomidine, the plasma concentration levels are not
reported. Additionally, dexmedetomidine is approximately
8 times more selective (alpha 2 versus alpha 1) than cloni-
dine [28,31], and so pharmacokinetic data on dexmedeto-
midine cannot be used to estimate effective doses of
clonidine. We thus have to extrapolate from pharmacoki-
netic data on clonidine used for other purposes. We know
that clonidine has both sedative and anxiolytic effects, and
that these centrally mediated effects are closely related to
plasma concentration levels [53,54].
In a study of adolescents with chronic fatigue syn-
drome, a dosage of 50 μg twice per day resulted in a me-
dian trough concentration (C0) at 0.21 μg/L after 14
days of treatment, rising to a median level of 0.41 μg/L
(Cmax) two hours after administration of one regular
dose of 50 μg [55,56]. In a study of healthy normotensive
subjects, treatment with oral clonidine 225 μg daily for
one week resulted in a steady state of 0.3-0.35 ng/ml.
After intake of one 75 μg tablet, the serum level then
increased to 0.7 ng/ml at 2 h. There was a significant
relationship between the plasma level of clonidine and
sedation [53]. In subjects receiving oral clonidine 100 μg
twice per day for 6 weeks, plasma concentration ranged
between 0.4 and 0.7 ng/ml (levels 2 hours after intake of
100 μg) [52]. Another study found that a single dose of
75 μg gave a Cmax of 0.66 ng/ml after achieving steady-
state with two 75 μg doses [57].
The present patient population (elderly with a glom-
erular filtration rate [GFR] limit of > 30 ml/min) may
have a longer half life of clonidine due to a diminished
renal capacity as compared to younger. Altough the
metabolism of clonidine is hepatic, varying amounts
of unmetabolised clonidine is secreted renally. Conse-
quently, patients may also have a higher risk of adverse
events related to the study drug. We therefore choose a
lower dosage, considered safe, of 75 μg twice per day.
Loading doses
The loading dose is based on half-life. Clonidine follows
first order kinetics for elimination, and thus the mean
steady state is proportional to the daily dose. DoublingDosage
st loading dose. 75 μg every 3rd hour until maximum
4 doses, (e.g.: at 2, 5, 8 and 11 p.m)
or if RASS is −3 or less
more study medication
se the next morning.
s if IMP will be given or not
or if RASS is −3 or less
will be given until the
75 μg BID, at 8–9 a.m and 8–9 p.m
s if IMP will be given or not
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centration level. A study showed that a single oral dose
of 75ug clonidine gave Cmax 0.29 ng/ml, 150ug gave
Cmax 0.61 ng/ml and 250ug gave 1.2 ng/ml [45]. We
will administer up to 300 μg the first day, but as 75 ug
every three hours. Thus, the theoretical Cmax at day
one would be significantly lower than 1.2 ng/ml, due to
elimination of the drug. How much lower is difficult to
estimate, given the large variability in half-life (5 to
25 hours).
The expected maximum hypotensive effect correlates
well with the Cmax time-point occurring after 2 hours.
There is an interindividual difference in the pharmaco-
dynamic response to clonidine. Our loading dose is
dependent on and monitored by the individual patients'
haemodynamic response (blood pressure and heart rate).Safety review
A safety review will be done after we have recruited 20
patients (10 placebo and 10 clonidine). Recruitment of
the additional 80 patients will be halted until we have
made an assessment of the serum concentration levels,
pharmacokinetics and -dynamics (the haemodynamicTable 2 List of endpoints and measurements for efficacy asse
Endpoint
Primary
Delirium trajectory
Secondary (also with subanalyses for subsyndromal delirium
and hypoactive/hyperactive/mixed delirium)
Time-to-first delirium resolution
Incidence of “full-scale” delirium
Severity of delirium
Delirium subtype
Use of “rescue medication”/additional drugs (as other sedatives,
analgetics and antipsychotics)
Length of hospital stay
Patient distress
Cognitive function in follow-up after 4 months
Independence in follow-up after 4 months
Pharmacokinetic response to clonidine
Pharmacodynamic response to clonidine
Biomarkers
Institutionalisation
Survival
Safety
Side effects of clonidine/in-hospital complicationsresponse) in these initial 20 patients. These data will
then guide further dosage for the subsequent 80 pa-
tients. We are aiming for serum concentration levels be-
tween 0.3 and 0.7 ng/ml, but may accept a small number
of single measures above this range. Blood samples for
serum concentration measurement will be taken 3 hours
after the patient has taken the study drug (each time) on
day 1 and just before administration of study drug be-
tween 0800 and 0900 on day 2. The serum concentra-
tion levels and pharmacodynamic responses will be
assessed by an independent Data Monitoring Commit-
tee. The determination of the further dosage plan will
thus be based on both pharmacokinetics/serum concen-
tration levels and the individual patients´ haemodynamic
responses. The further dosage plan will be approved by
The Norwegian Medicines Agency.Study objectives
Primary endpoint
The endpoints and measurements for efficacy assess-
ment are listed in Table 2. Our primary objective is to
explore the potential superiority of clonidine vs placebo
in decreasing delirium duration and severity, measuredssment
Measurements for efficacy assessment
MDAS
DSM-5
DSM-5
MDAS, OSLA
MDAS, OSLA, DelApp
Registration of use of all medication
Registrations
Checklist of Nonverbal Pain Indicators
MMSE-NR, Clock drawing test, Ten-words memory test,
Trial making test A and B, IQCODE, CDR
Barthel ADL, NEADL
Serum drug concentrations
BP, HR, ECG, RASS, OSLA, symptoms of bradycardia,
orthostatic hypotension or other side-effects
Blood samples
Registrations
Registrations
BP, HR, ECG, sedation (RASS, OSLA), and any symptoms of
bradycardia, orthostatic hypotension or other side-effects
Neerland et al. BMC Geriatrics  (2015) 15:7 Page 5 of 14by Memorial Delirium Assessment Scale (MDAS) [58] in
patients diagnosed with delirium or subsyndromal delir-
ium (according to Diagnostic and Statistical Manual of
Mental Disorders, DSM-5 [59]). The primary endpoint,
the trajectory of delirium, is the severity of delirium
(measured by MDAS) over time.
Secondary endpoints
We will compare the actively treated group with the pla-
cebo group with respect to secondary endpoints shown
in Table 2. The main secondary endpoint is the duration
of delirium monitored daily by the DSM-5 diagnostic
criteria. We will also study the feasibility of oral cloni-
dine in a geriatric ward and effects of clonidine upon a
variety of outcomes as a means to design a potentiallyAssessed for eligib
Follow-up after 4 months (n=?)
Lost to follow-up in-hospital (n=?)
Discontinued intervention (n=?)
(Reasons recorded)
Analysed (n=?)
Follow-up at discharge (n=?)
Lost to follow-up in-hospital (n=?)
Discontinued intervention (n=?)
(Reasons recorded)
Analysed (n=?)
Allocated to intervention (clonidine) (n=50)
Received allocated intervention (n=?)
Did not receive allocated intervention (n=?)
(Reasons recorded)
Alloca
Follow-u
anal
Randomised
Enrollment
Figure 1 CONSORT Study flow diagram.more definite study later. We will do per protocol ana-
lyses and exposure-response analyses based on plasma-
concentration.
Methods and design
Study design
The Oslo Study of Clonidine in Elderly Patients with
Delirium (LUCID) is a randomised, placebo-controlled,
double-blinded, parallel group study with 4 month pro-
spective follow-up (Figure 1). We aim to include 100
inpatients with delirium (or subsyndromal delirium) in
an acute geriatric ward. Patients will be randomised to
orally administrated clonidine or placebo until delirium
free (by DSM-5 criteria) or no subsyndromal delirium
for 2 days, or after a maximum of 7 days treatment. Ifility (n > 100)
Ineligible (n=?)
(Reasons recorded)
Follow-up at discharge (n=?)
Lost to follow-up in-hospital (n=?)
Discontinued intervention (n=?)
(Reasons recorded)
Analysed (n=?)
Allocated to control (placebo) (n=50)
Received allocated intervention (n=?)
Did not receive allocated intervention (n=?)
(Reasons recorded) 
Follow-up after 4 months
Lost to follow-up in-hospital (n=?)
Discontinued intervention (n=?)
(Reasons recorded)
Analysed (n=?)
tion
p and 
ysis
 (n=100)
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having delirium/subsyndromal delirium), before 7 days,
we will end the treatment 24 hours before discharge.
Assessment of haemodynamics (blood pressure, heart rate
and ECG) and of delirium will be performed daily until
discharge, or a maximum of 7 days after end of treatment.
This study will be conducted in compliance with the
Declaration of Helsinki and with ICH/Good Clinical
Practice. Registration of patient data will be carried out
in accordance with national personal data laws. The
study design, protocol and informed consent procedures
are approved by the Regional Medical Ethics Committee
and the Norwegian Medicines Agency (EUDRACT
number 2013-000815-26). The study is also registered at
www.clinicaltrials.gov (NCT01956604).
Study population
We will recruit patients >65 years of age from the acute
geriatric ward at Oslo University Hospital. These pa-
tients are usually acutely admitted, arriving directly from
the emergency department, with considerable multimor-
bidity and polypharmacy, with a high prevalence of
infections, dehydration, acute cardiac problems, general
medical problems, functional decline and delirium. They
might be included at admission (prevalent delirium), or
during the stay (incident delirium). Patients with prevalent
delirium/subsyndromal delirium must be included within
approximately 48 hours after admission and patients
with incident delirium/subsyndromal delirium must be
included within approximately 48 hours of symptom
onset. All patients must have current delirium/subsyn-
dromal delirium at the time of inclusion.
Screening
Patients admitted to the study ward will go through a sim-
ple screening process (see Table 3). This screening is a
combination of the Single Question in Delirium (SQiD)
(asking one question to the patient's friend or relative:” Do
you think (name) has been more confused in the last two
weeks?”) [60], combined with two simple attention tests
(reciting the days of the week and months of the yearTable 3 Screening for delirium in patients at the acute geriat
Screening SQiD
Drowsiness
Cannot recite m
Cannot recite a
Staff suspect de
Ascertainment of delirium or subsyndromal delirium If Yes in any bo
Inclusion All DSM-5 crite
If the patient mbackwards). If any of these tests are positive, if the patient
is drowsy, or if the nurse and/or the treating physician for
other reasons suspects delirium, ascertainment of delirium
or subsyndromal delirium will be performed.
Diagnosis of delirium and subsyndromal delirium
The diagnosis of delirium will be made by the study physi-
cians according to DSM-5 criteria by using a standardised
procedure (Table 4). Level of arousal will be assessed using
the Richmond Agitation and Sedation Scale (RASS) [61]
and the Observational Scale of Level of Arousal (OSLA)
[62]. Attention will be evaluated using objective tests
(Table 4) and observations by the examiner of the patient´
s distractibility, comprehension and tendency to lose the
thread of conversation. We will also use a smartphone
(Android) software application, the “DelApp” [63], which
incorporates an initial test of level of arousal followed by a
test of attention. Acute change in the patient´s mental sta-
tus, and fluctuation of any disturbance, will be ascertained
through informant history from nursing staff and carers
and also derived from clinical notes. Assessment of add-
itional mental status disturbances will be performed by
asking the patient a list of pre-defined questions (Table 4)
in addition to information derived from nursing staff and
clinical notes. All these assessments will be used in com-
bination in relation to the DSM-5 criteria. The objective
indicators (described above and in Table 4) will be supple-
mented by the assessor´s judgement regarding subjective
features and a final diagnosis made.
Subsyndromal delirium will be defined as evidence of
change, in addition to any one of these: (a) altered arousal,
(b) attentional deficits, (c) other cognitive change, (d)
delusions or hallucinations. DSM-5 criteria D and E
must be met. The severity of delirium will be assessed
for all included patients by MDAS [58], based on the tests
and information described above. We will also register the
Confusion Assessment Method (CAM) [64] daily.
Evaluating patient eligibility
According to the inclusion and exclusion criteria, ECG,
creatinine/eGFR, body weight and blood pressureric ward
Yes No
□ □
□ □
onths backwards (unable to reach July) □ □
ll the weekdays backwards □ □
lirium □ □
x, do diagnostic procedure (DSM-5), Table 4
ria (delirium) or subsyndromal delirium→ can be included
eets all the inclusion criteria, the patient will be included
Table 4 Diagnostic algorithm for DSM-5 delirium
DSM-5 criteria Tests to be performed or information needed DSM-5 criteria
fullfilled?
YES NO
A. Disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift
attention) and awareness (reduced orientation to the environment).
Evaluation TEST Cut off (definition of
inattention)
Daily Digit span forward Less than 5 forward
Daily Digit span backward Less than 3 backwards
Daily SAVEAHAART 2 or more errors
Initial diagnosis only Days of the week in reverse order Any error
Initial diagnosis only Months of the year in reverse order Unable to reach July
Initial diagnosis only Count backwards from 20 to 1 Any error
Observation (by the examiner):
Distractibility. Comprehension. Tendency to lose the tread
of conversation
The “DelApp” [level of arousal test followed by
counting of serially-presented lights. Cut-off 7/8 out of 10]
B. The disturbance develops over a short period of time (usually hours to a few days),
represents a change from baseline attention and awareness, and tends to fluctuate in
severity during the course of a day.
Informant history from patient´s carers and nursing staff
Questions to carer/ nursing staff or derived from clinical notes:
Has there been a sudden change in the patient´s mental state?
Does the patient seem to be better at any period in the day
compared to other times?
Has the level of consciousness been altered (drowsy/not
interacting or agitated)?
Sleep-wake cycle disturbances?
C. An additional disturbance in cognition (e.g., memory deficit, disorientation, language,
visuospatial ability, or perception).
Questions to the patient:
Orientation to time, place and person
Recall (3 words)
Why are you in hospital? Will a stone float in water? Are there
fish in the sea? (any error = disorganised thinking)
Questions to carer/ nursing staff or derived from clinical notes:
Has there been any…:
Perceptual disturbances? Sleep-wake cycle disturbances? Memory
disturbances? Psychotic symptoms?
Psychomotor abnormalities?
D. The disturbances in criteria A and C are not explained by another preexisting, established,
or evolving neurocognitive disorder and do not occur in the context of a severely reduced
level of arousal, such as coma.
Information from history/chart/clinical assessment
N
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Table 4 Diagnostic algorithm for DSM-5 delirium (Continued)
E. There is evidence from the history, physical examination, or laboratory findings that the
disturbance is a direct physiologic consequence of another medical condition, substance
intoxication or withdrawal (i.e., because of a drug of abuse or to a medication), or exposure
to a toxin or is because of multiple etiologies.
Information from history/chart/clinical assessment
Delirium based on the tests and information above? All DSM-5 criteria fulfilled Yes □ No □
Subsyndromal delirium based on the tests and information above? Defined as evidence of change, in addition to any one of these:
(a) altered arousal, (b) attentional deficits, (c) other cognitive
change, (d) delusions or hallucinations.
Yes □ No □
Criteria D and E must be met.
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gibility will be agreed with the treating physician on
the ward. Capacity will be assessed and informed con-
sent (and/or) assent obtained (see below).
Inclusion and exclusion criteria
Patients with delirium or subsyndromal delirium will be
included in this study by the study physicians. We will
include patients with chronic cognitive impairment or
dementia as well as patients free from dementia. Nursing
home patients are eligible. Patients must be > 65 years
old, though the average age is expected to be more than
80 years. Further, the patient must be willing and able to
receive the study medication.
Inclusion criteria
All of the following conditions must apply to the pro-
spective patient at screening prior to receiving study agent:
 Patient > 65 years old admitted to the acute,
medical, geriatric ward
 Delirium or subsyndromal delirium within the last
48 hours
 Signed informed consent from patient or relatives
and expected cooperation of the patients for the
treatment and follow up must be obtained and
documented
Exclusion criteria
Patients will be excluded from the study if they meet
any of the following criteria:
 Symptomatic bradycardia, bradycardia due to sick-
sinus-syndrome, second- or third- degree AV-block
(if not treated with pacemaker) or any other reason
causing HR <50 bpm at time of inclusion [44].
 Symptomatic hypotension or orthostatic
hypotension, or a systolic BP <120 at the time of
inclusion
 Ischemic stroke within the last 3 months or critical
peripheral ischemia
 Acute coronary syndrome, unstable or severe coronary
heart disease (symptoms at minimal physical activity;
NYHA 3 and 4) and moderate to severe heart failure
(NYHA 3 and 4). (Acute coronary syndrome is defined
according to international guidelines)
 A diagnosis of polyneuropathy, phaeochromocytoma
or renal insufficiency (estimated GFR < 30 ml/min
according to the MDRD formula) [44]
 Body weight <45 kg
 Considered as moribund on admission
 Unable to take oral medications
 Current use of tricyclic antidepressants, monoamine
reuptake inhibitors or ciclosporin
 Previously included in this study Adverse reactions to clonidine or excipients (lactose,
saccharose)
 Not speaking or reading Norwegian
 Any other condition as evaluated by the treating
physician
Informed consent and enrolment
Informed consent is a well-known challenge in studies
of delirium [65,66], both due to the nature of delirium
itself and the fact that people with underlying dementia
are most at risk of developing delirium. Cognitively
intact patients are included in this study on the basis
of written, informed consent. We have developed a com-
prehensive information leaflet for cognitively intact
patients and a simplified and shortened version for those
who are partly or not at all competent to give their
consent. For patients considered to lack capacity (due to
severe delirium and/or dementia), but who are willing to
take part, we will obtain proxy informed consent from a
close relative. Consent to remain in the research will be
obtained as soon as possible if capacity returns. Due to
the importance of including patients as soon as possible
after the diagnosis of delirium is made, the close rela-
tives may give verbal consent (by phone) before random-
isation and the written consent will be obtained as soon
as possible after inclusion. We have good experience
with this method from previous studies in our research
group [67].
Randomisation and blinding
The randomisation is based on computer-generated ran-
dom numbers, and will be carried out by a statistician.
The randomisation schedule will be distributed to the
producer of the study medication, and capsules made
accordingly. The randomisation will be stratified with
respect to whether or not the patient was admitted from
a nursing home, in order to balance the groups with
respect to pre-admission cognitive decline, independ-
ence and comorbidity, all important prognostic factors.
Study medication
Each capsule (CAPSUGEL) will contain either 75 μg
Catapresan (clonidine hydrochloride) or 75 μg placebo,
and will be produced and labeled by Kragerø tablettpro-
duksjon A/S. The capsules containing active medication
and placebo will look identical. If other medications are
indicated for the treatment of delirium, the treating
physician will prescribe this as “standard care”.
Monitoring and safety
BP and HR will be monitored 3 hours after each loading
dose (day 1) and then just before every dose. If there are
signs of significant hypotension (systolic BP <100 mmHg) or
bradycardia (heart rate <50 beats/min), further monitoring
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whole treatment period blood pressure and heart rate
will be assessed twice per day. ECG, serum creatinine,
blood glucose and a clinical assessment by a physician
(hydration, side-effects, RASS [61] and OSLA [62]) will be
performed daily. Orthostatic BPtests will be performed
during the hospital stay at day 5, 6 or 7 at 1100 (approxi-
mately 3 hours after administration of study drug).
For all patients, drug concentration (mean concentra-
tion just before intake and Cmax 3 hours after intake)
will be measured at day 5, 6 or 7. The pharmacokinetics
of clonidine varies inter-individually, possibly influencing
individual treatment responses. But due to the short
treatment period, measurement of drug concentration
for individual drug modification is not feasible.
Data collection
Demographic data, medical history, information regard-
ing the acute underlying medical disease(s), drug use
and proxy information will be collected during the
hospital stay. Once included in the study, patients will
be visited daily for efficacy and safety evaluations by the
study physicians (geriatricians) or by the consultant
on-call during the weekend.
We will assess pre-existent functional and cognitive
status by asking the patient’s primary caregiver (the
best available source) to complete questionnaires to as-
sess the patient´s functional and cognitive state two
weeks prior to hospital admission. Functional status
will be assessed using the Barthel ADL Index [69] and
the Nottingham Extended ADL Index (NEADL) [70].
To ascertain prior long-term cognitive decline we will
use the Informant Questionnaire on Cognitive Decline
in the Elderly (IQCODE) [71] and the Clinical Demen-
tia Rating Scale (CDR) [72]. The Mini-Mental State
Evaluation – Norwegian version (MMSE-NR) [73,74]
will be performed at baseline and at discharge for the
purposes of general cognitive screening. The Cornell
Depression Scale [75,76] is based on proxy information
and will be used to evaluate the degree of depressive
symptoms.
Grip strength of the dominant hand will be measured
using hand-held dynamometry once during the hospital
stay and at follow-up after 4 months. The severity and
number of comorbidities will be scored using the Cumula-
tive Illness Rating Scale (CIRS) [77]. The level of physio-
logical disturbance will be assessed by using Acute
Physiology and Chronic Health Evaluation II (APACHE
II) [78], the version utilising venous bicarbonate rather
than arterial blood gases. Body Mass Index is registered
as a marker of nutritional status.
We will use the algorithm described in the section
above and in Table 4 to diagnose delirium (or subsyn-
dromal delirium) according to the DSM-5 criteria.We will also collect data about patient distress, using
items from The Checklist of Nonverbal Pain Indicators
(CNPI) [79]. Possible and suggestive causes of delirium
are registered in each case at discharge.
Laboratory tests and blood sample procedures
Data from routine blood samples taken at admission will
be recorded (including Erythrocyte Sedimentation Rate,
Haemoglobin, Leukocytes, Creatinine, Electrolytes, C-
reactive protein, Albumin, Thyroid stimulating hormone
and free Thyroxine levels).
All patients will have blood drawn for drug concentra-
tion levels at day 5, 6 or 7 (just before and 3 hours after
intake of study medication), to be able to compare pos-
sible effects and side-effects to the actual plasma-
concentration at the end of the trial.
Our study population is expected to have significant
acute and chronic comorbidity. In this aspect, looking
for new biomarkers is challenging, as we do not have a
delirium-free control group. We will however take blood
samples (serum and plasma) for biomarkers at inclusion,
at mid-stay (day 3–5) and at discharge, to explore
markers already known to be associated with delirium.
Interesting biomarker candidates include S100B [80,81],
neopterin [82], IGF-1 [83], MMP-9, protein C, sTNFR1
[84]. The serum and plasma will be stored in a biobank
freezer at Oslo University Hospital together with blood
stored in EDTA tubes for possible DNA-analyses.
Follow-up assessments
We will phone the patient or care-taker by phone one
week after the end of the treatment to consider possible
side-effects/ rebound effects or relapse of the delirium.
No physical examination or psychometric tests will be
performed. We will register the level of care, and
whether the patient has been discharged home or to an
institution.
Four months after discharge, a home visit will be done
to perform cognitive tests (see Table 2). Based on proxy
information, we will evaluate each patient´s level of in-
dependence and functional and cognitive status. We will
assess the presence of persistent delirium (according to
DSM-5 criteria) and subsyndromal delirium and perform
the MDAS. Grip strength will be measured. Level of
care, any readmissions to hospital and cumulative mor-
tality will be registered.. Causes of death will be ascer-
tained from the Cause of Death Register.
Criteria for patient discontinuation
Patients may be discontinued from study treatment and
assessments for several reasons. These include: omission of
more than 3 following dosages, voluntary discontinuation
by the patient, safety reasons as judged by the study phys-
ician or treating physician, or significant non-compliance
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patient withdrawn from the study will be included in
the statistical intention-to-treat analysis. If possible, a
final assessment shall be made (end of study visit) and
the reason for discontinuation shall be recorded. Pro-
gression of delirium is not a discontinuation criterion,
as the trajectories are variable and impossible to predict.
Progression of delirium may however make the patient
unwilling to further participate. If any of the exclusion
criteria appear during the treatment, treatment will be
discontinued. (Except changes in blood pressure and
heart rate, which will be managed as described in the
dosage plan).
Statistical analysis
The primary endpoint is the repeated measurements of
MDAS over time. Differences in the MDAS trajectories
between the treatment groups will be analysed by a
mixed linear model. In addition we will, as a secondary
endpoint, compare the time to resolution of delirium as
measured by DSM-5. The Kaplan Meier method and the
logrank test will be applied. In addition a Cox propor-
tional hazards model will be applied to estimate hazard
ratios. The additional different secondary endpoints will
be analysed by t-tests when variables are continuous and
by chi-square tests when variables are categorical. Pa-
tient survival will be compared between groups by the
logrank test and Cox proportional hazards model.
For the comparison of the MDAS trajectories no
adjustment for multiplicity will be applied. If a sta-
tistically significant difference between the MDAS
trajectories is demonstrated, analyses of secondary
endpoints will be performed without any formal ad-
justment for multiplicity. If any conclusion on efficacy
is to be drawn based on a secondary endpoint only, a
simple Bonferroni adjustment (dividing the 5% level
with the actual number of tests performed) will be
applied. If the use of additional antipsychotics differs
between treatment groups, the amount calculated as
haloperidol equivalents [68] will be included in the
statistical model.
Sample size, statistical power and statistical analysis
Based on the expected number of patients fulfilling the in-
clusion criteria within 36 months a sample size of n = 100
was chosen. Inclusion of 100 patients would lead to a
power of only 71% to detect an absolute treatment differ-
ence of 25% in proportion recovered according to DSM-%
(40% vs 65%). Correspondingly, using MDAS at one single
point in time as the response measure would lead to ap-
proximately 80% power assuming a standard deviation of
9 and a difference in mean MDAS score of 5. Thus, ana-
lyzing treatment efficacy at only one point in time would
lead to low power. An analysis of repeated measurementswill reduce random variability and thereby increase power.
The primary analysis is therefore a mixed linear model
taking all MDAS measurements into account.
The expected efficiency gain is difficult to estimate
precisely, but assuming a standard deviation of 9 on the
MDAS and a correlation between measurements of r = 0.5,
the power would be around 95% to detect a mean MDAS
difference of 5 or a power of 80% to detect a mean
difference of 3.5 between groups.
Discussion
Delirium is a severe and common condition among acute
hospitalised elderly patients, and the options for pharmaco-
logical treatment are sparse. To our knowledge, no rando-
mised placebo controlled trial investigating treatment of
delirium with clonidine or other alpha-2-adrenoreceptor
agonists has yet been done in non-critically ill medical
patients. It has been recommended [85,86] that future stud-
ies on pharmacological treatment of delirium should have
less restrictive exclusion criteria, in order to avoid low ex-
ternal validity. Further, future studies should ensure stratifi-
cation according to known underlying risk factors for
delirium. The trials should then have a true placebo arm
and use validated instruments for delirium assessments.
We have planned this trial according to these guidelines.
The results of our study will be more clinically rele-
vant if the medication is easy and safe to administer to
patients in a general ward, without the need for invasive
monitoring. Frail and demented patients are more prone
to develop delirium, and the treatment regimen should
be feasible for this large group of patients. Thus, it is
important that the exclusion criteria are not too strict,
and we will therefore include patients with dementia
and patients from nursing homes in this trial.
Delirium is a clinical diagnosis, based on history, infor-
mation from proxies, mental status examination and
evaluation of an underlying medical cause. There is no
single simple test, neither psychometric nor physio-
logical, to ascertain delirium. We have described the
procedure that we will use to make the final diagnosis
according to the DSM-5 criteria. All assessments of
delirium will be made by the investigators (geriatricians
trained in delirium evaluation) during weekdays, and by
geriatricians on call in the weekends.
The primary outcome in this study is the trajectory
of delirium, measured daily by MDAS. Due to features
common in studies of delirium (small sample sizes,
sample attrition, fluctuation course of the disease and
spontaneous recovery), techniques that use all available
data and take a global (as opposed to end-of-trial) per-
spective are preferred [87]. Using longitudinal trajector-
ies as the main outcome will almost always have greater
power than end-of-trial analyses [87-89], as well as redu-
cing the problem with missing data.
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have a differential impact on hyperactive versus hypoac-
tive subtypes of delirium, or even only on certain fea-
tures of delirium (e.g. inattention). The sample size of
this study is too small to give conclusive results regarding
secondary endpoints. However, these secondary objectives
are exploratory and may generate new hypotheses and
give direction for future studies.
Any positive results of clonidine on delirium symp-
toms will also contribute to the discussion about the
underlying pathophysiology and the role of the auto-
nomic nervous system in delirium. Studies of dexmede-
tomidine have showed promising results with respect to
delirium duration and severity in the intensive care unit
patients, but it is still uncertain weather this is an
opioid- and benzodiazepine-sparing effect alone or if
dexmedetomidine has truly delirium modulating effects
[36,37]. Any positive effect of clonidine compared to pla-
cebo may indicate that the sympathetic nervous system
and related stress systems are involved in the underlying
pathophysiology of delirium.
Conclusion
LUCID will contribute to knowledge about the pharma-
cological treatment of delirium in the elderly, and may
also shed light on relevant pathophysiological hypotheses.
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